Search

PHILIP TAGARI SWITCHES AMGEN'S DISCOVERY LAB FOR INSITRO'S MACHINE LEARNING TOOLS; CEO JOAQUIN DUATO TO CHAIR J&J'S BOARD

Philip Tagari In February, Philip Tagari will take a few days of retirement and then immediately return to industry. He won't be leading...

CinCor Hypertension Drug Flunks Study, But the Biotech Still Sees a Phase 3 Path

CINCOR HYPERTENSION DRUG FLUNKS STUDY, BUT THE BIOTECH STILL SEES A PHASE 3 PATH

Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled...

 
 
 
New Gene Therapy Biotech Telaria Launches With Rare Skin Disease Focus

NEW GENE THERAPY BIOTECH TELARIA LAUNCHES WITH RARE SKIN DISEASE FOCUS

Telaria is developing a gene therapy for the rare skin disorder recessive dystrophic epidermolysis bullosa. The company was formed...

SCIENTIST - NOVARTIS - CARLSBAD, CA

Navigate Biopharma, a fully owned subsidiary of Novartis, provides assay development, clinical trial testing, and companion diagnostics...

 
 
 
Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds

ACRIVON NETS $100M FOR PROTEIN TECH THAT PICKS PATIENTS FOR TARGETED CANCER MEDS

Eli Lilly's stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage...

ILLUMINA BECOMES THE LATEST DOMINO IN LAYOFFS TREND, CUTTING AROUND 5% OF ITS WORKFORCE

The third quarter blues are hitting biopharma hard as the past weeks have seen both big pharmas and smaller biotechs axing portions...

 
 
 
GSK Digital & Tech Executive Takes Drug-Hunting Inspiration from Outer Space

GSK DIGITAL & TECH EXECUTIVE TAKES DRUG-HUNTING INSPIRATION FROM OUTER SPACE

GSK is making greater use of artificial intelligence and computational techniques as part of its drug discovery efforts. Speaking during...

Elizabeth Holmes requests home confinement instead of prisoning ahead of formal sentencing

ELIZABETH HOLMES REQUESTS HOME CONFINEMENT INSTEAD OF PRISONING AHEAD OF FORMAL SENTENCING

Ex-Theranos CEO Elizabeth Holmes will face sentencing this week, and has asked the court to...

 
 
 
FDA Again Spurns BrainStorm's ALS Data, This Time With Official Refusal

FDA AGAIN SPURNS BRAINSTORM'S ALS DATA, THIS TIME WITH OFFICIAL REFUSAL

BrainStorm Cell Therapeutics' stem cell therapy for amyotrophic lateral sclerosis received an FDA refuse-to-file letter, correspondence...

Getting off the PBM Merry-go-Round: How Late-stage Offer Tricks Take Employers for a Ride

GETTING OFF THE PBM MERRY-GO-ROUND: HOW LATE-STAGE OFFER TRICKS TAKE EMPLOYERS FOR A RIDE

Requiring that PBMs bid on a per member per month guarantee would reduce the employer's uncertainty by securing the actual per member...

 
 
 
With Secreted Proteins Map, Juvena Finds Path to $41M for New Regenerative Meds

WITH SECRETED PROTEINS MAP, JUVENA FINDS PATH TO $41M FOR NEW REGENERATIVE MEDS

Juvena Therapeutics is developing secreted protein drugs built on new knowledge gleaned from proprietary technology that maps these...

BIOTECH FUNDING ROUNDUP: HI-BIO'S HAUL, CONCERTO'S CASH, LUSARIS'S LAUNCH & MORE

Emalex Biosciences raised $250 million, a Series D round of funding that was the biggest biotech financing of the past week. Other...

 
 
 
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue

FOR NEURO BIOTECH LUSARIS, DEPRESSION THERAPY STARTS BY LIFTING THE TONGUE

Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to...

Rubius's New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%

RUBIUS'S NEW CELL THERAPY STRATEGY RUNS OUT OF TIME & MONEY; WORKFORCE IS CUT BY 82%

Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based...

 
 
 

REGEN BIOPHARMA, INC. TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON NOVEMBER 9, 2022

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive...

Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout

THERMO FISHER BETS BIG ON BLOOD CANCER, IMMUNE DIAGNOSTICS WITH $2.6B BINDING SITE BUYOUT

Thermo Fisher Scientific's acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers...

 
 
 
Report: Cancer deaths are down but pancreatic cancer is growing, racial disparities persist

REPORT: CANCER DEATHS ARE DOWN BUT PANCREATIC CANCER IS GROWING, RACIAL DISPARITIES PERSIST

Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung...

Agios sells cancer drug royalty, raising $132M to fund rare disease mission

AGIOS SELLS CANCER DRUG ROYALTY, RAISING $132M TO FUND RARE DISEASE MISSION

Agios Pharmaceuticals sold royalties to an approved cancer drug to get immediate cash to support its new focus on rare diseases. Earlier...

 
 
 

REGEN BIOPHARMA, INC. EXPLORES THE CAR-T THERAPEUTIC SPACE

Understanding CAR-T Mechanism of Action SAN DIEGO, Oct. 26, 2022 /PRNewswire/ - Regen BioPharma, Inc. and has filed several patents...

Astellas takes a stake in Taysha and gets a chance at next big gene therapy buyout

ASTELLAS TAKES A STAKE IN TAYSHA AND GETS A CHANCE AT NEXT BIG GENE THERAPY BUYOUT

Astellas has purchased an equity stake in Taysha Gene Therapies in a $50 million deal that gives it an option to license the company's...